KRAS inhibitor-9 is primarily used in the field of oncology, specifically targeting cancers driven by KRAS mutations. It is designed to inhibit the activity of mutant KRAS proteins, which are often implicated in uncontrolled cell growth and proliferation. This makes it a promising candidate for treating various cancers, including lung, colorectal, and pancreatic cancers, where KRAS mutations are prevalent. By blocking the signaling pathways activated by mutant KRAS, it helps to slow down or stop tumor growth. Its application is being explored in preclinical and clinical studies to evaluate its efficacy and safety as a targeted therapy for KRAS-driven malignancies.